Tumor | Location | Diagnostics | Treatment | Prognosis | Palliative tx |
---|---|---|---|---|---|
Lymphoma | -LNs (K9) | -Cytology, CBC/CHEM/UA, flow cytometry or PARR, +/- AXR/AUS and CXR |
-L-CHOP, single agent dox (B) or lomustine (T) -Lomustine + pred |
B: 1 yr, 25% 2 yrs (6m if sick/T cell) -1-3 months w/pred alone |
-Pred 2 mg/kg/d, taper to 0.5-1 mg/kg |
-Cutaneous (K9) | -Biopsy | -Lomustine + pred | -6-9 months | -Pred, antibiotics, derm meds | |
-Cat | -Cytology (mass, fluid), FeLV/FIV, CBC/CHEM/UA |
-L-CHOP, COP, or lomustine |
-6-9 months, 10-25% long term survivors (years) if CR. Shorter MST FeLV+. | -Prednisolone 5-10 mg/cat/d | |
Mast cell tumor | Cutaneous | -Cytology: mass, regional LN, +/- spleen -Biopsy w/histopathology -CBC/CHEM/UA -AUS, CXR +/- MCT panel (high mitotic index, metastatic, large size, location, etc.) |
-SX -Stefonta injection -XRT (if dirty margins) -Chemo if high grade/metastatic: vinblastine/pred, Palladia, lomustine |
-Highly variable -Complete removal/low grade: “cure” -Dirty margins + XRT, no mets: years. -High grade/metastatic: ~6 months, 1-2 yrs with chemo in some cases |
-Pred 1-2 mg/kg/d -Benadryl 2 mg/kg BID -Prilosec 0.5-1 mg/kg/d -6-12 months w/palliative chemo, 1+ yr w/XRT + Palladia |
-SQ | -Cytology of mass, regional LN -CBC/CHEM/UA -Biopsy w/histopathology -AUS, CXR if concern for aggressive tumor (MCT panel not validated for SQ) |
-Unresectable: chemo +/- palliative XRT -SX -Stelfonta if distal to elbow or hock |
-MST not reached, >92% alive at 2 years -Shorter survival if high MI, infiltrative growth pattern, multinucleation on biopsy |
-Same as above | |
Osteosarcoma | -Appendicular | -Rads (limb, CXR) -CBC/CHEM/UA +/- Cytology or biopsy |
-Amp + chemo (carboplatin) -RT: 70-95% improve |
-12+ months. CXR q2-3 months -Pain control 2-4 months. Can repeat RT -3-4 months |
-NSAID, gabapentin, Tylenol IV, zoledronate |
-Axial | -Rads (affected area, CXR), +/- CT for surgical planning, CBC/CHEM/UA, cytology or biopsy | -SX if possible | -~5 months, high rate recurrence | -See above, steroids if located on skull/neuro | |
-Appendicular (cats) | -Same as dogs | -Amputation +/- chemo in some cases | -2+ years | -See above (not Tylenol) | |
Melanoma | -Oral | -Cytology: mass, draining lymph node, CBC/CHEM/UA, CXR, biopsy. | -Complete removal or RT + Oncept vaccine | -1-2 years, shorter with advanced stage | -Pain meds, soft food, magic mouthwash |
-Digit | -Cytology: mass, draining lymph node, CBC/CHEM/UA, CXR, biopsy. | -Digit amputation + Oncept vaccine | -15+ months (longer if no mets, 48% alive at 2 and 3 yrs) | -Pain meds | |
-Cutaneous | -Biopsy of mass +/- lab work, lymph node cytology, CXR if malignant | -Removal, +/- Oncept vaccine if high risk | -3+ years. Shorter if high MI, high Ki67, nuclear atypia, large size, metastasis | +/- Antibiotics, topical meds, NSAIDs | |
HAS | -Spleen | -CBC/CHEM/UA, AXR/AUS, CXR, biopsy | -Splenectomy + chemo (dox, MTC), I’m Yunity or propranolol | -5-7 months | -Yunnan Biayao, pain meds or NSAIDs, I’m Yunity |
-SQ/IM | -CBC/CHEM/UA, AUS, CXR, biopsy. +/- CT for surgical planning | -Removal + chemo | -SQ: 5 months to 3 years depending on study -IM: 5-9 months |
-Same as above | |
Soft tissue sarcoma | -Skin | -CBC/CHEM/UA, CXR, cytology or biopsy of mass | -Remove with wide margins -Narrow excision + RT or MTC -Chemotherapy only for grade III/high |
-Typically cured (clean margins, narrow margins with RT) -High grade 50% metastasize |
-Palliative RT -Pain meds |
TCC | -Bladder, prostate | -CBC/CHEM/UA/urine culture -Cytology of mass or CADET BRAF -Imaging: CXR, AUS |
-Remove if apical/small -NSAIDs -NSAIDS + IV or MTC chemo +/- RT |
-6-10 months generally -Shorter if urethral or prostatic, metastatic -Possibly longer survival with IMRT (21+ months) |
-NSAID -Antibiotics if secondary UTI -Stent, cystostomy tube |
KEY: SX=surgery; A/CXR=abdominal/chest x-ray; AUS=abdominal ultrasound; HSA=hemangiosarcoma; MTC=metronomic chemotherapy; RT=radiation therapy; TCC=transitional cell carcinoma; MTD=maximum tolerated dose; IMRT=intensity-modulated radiation therapy